Remco Berendsen

Mr. Remco Berendsen

Anesthesiology, Leiden University Medical Center, Leiden, The Netherlands
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2022 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
YHYannick J.J.M. Hazen
Yannick J.J.M. Hazen
PNPeter G. Noordzij
Peter G. Noordzij
BGBastiaan M. Gerritse
Bastiaan M. Gerritse
TSThierry V. Scohy
Thierry V. Scohy
SHSaskia Houterman
Saskia Houterman
AVAlexander B.A. Vonk
Alexander B.A. Vonk

1 July 2000 in Journal of Applied Physiology
Verified
Journal Article
Closed access
PDF file
AGA. B. Johan Groeneveld
A. B. Johan Groeneveld
RBRemco Berendsen
Remco Berendsen
ASAnton J. Schneider
Anton J. Schneider
IPIoannis A. Pneumatikos
Ioannis A. Pneumatikos
LSLeo A. Stokkel
Leo A. Stokkel
LTLambertus G. Thijs
Lambertus G. Thijs
The purpose of this study was to evaluate right ventricular (RV) loading and cardiac output changes, by using the thermodilution technique, during the mechanical ventilatory cycle. Fifteen critically ill patients on mechanical ventilation, with 5 cmH2O of positive end-expiratory pressure, mean respiratory frequency of 18 breaths/min, and mean tidal volume of 708 ml, were studied with help of a rapid-response thermistor RV ejection fraction pulmonary artery catheter, allowing 5-ml room-temperature 5% isotonic dextrose thermodilution measurements of cardiac index (CI), stroke volume (SV) index, RV ejection fraction (RVEF), RV end-diastolic volume (RVEDV), and RV end-systolic volume (RVESV) indexes at 10% intervals of the mechanical ventilatory cycle. The ventilatory modulation of CI and RV volumes varied from patient to patient, and the interindividual variability was greater for the latter variables. Within patients also, RV volumes were modulated more by the ventilatory cycle than CI and SV index. Around a mean value of 3.95 ± 1.18 l · min−1 · m−2 (= 100%), CI varied from 87.3 ± 5.2 (minimum) to 114.3 ± 5.1% (maximum), and RVESV index varied between 61.5 ± 17.8 and 149.3 ± 34.1% of mean 55.1 ± 17.9 ml/m2 during the ventilatory cycle. The variations in the cycle exceeded the measurement error even though the latter was greater for RVEF and volumes than for CI and SV index. For mean values, there was an inspiratory decrease in RVEF and increase in RVESV, whereas a rise in RVEDV largely prevented a fall in SV index. We conclude that cyclic RV afterloading necessitates multiple thermodilution measurements equally spaced in the ventilatory cycle for reliable assessment of RV performance during mechanical ventilation of patients.

6 October 2016 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
PDF file
MVMarieke E. van Vessem
Marieke E. van Vessem
MPMeindert Palmen
Meindert Palmen
LCLotte E. Couperus
Lotte E. Couperus
BMBart Mertens
Bart Mertens
RBRemco Berendsen
Remco Berendsen
SBSaskia L.M.A. Beeres
Saskia L.M.A. Beeres
OBJECTIVES: Vasoplegia has been described as a complication after cardiac surgery, particularly in patients with a poor left ventricular ejection fraction. The aim of this study was to assess the incidence, survival and predictors of vasoplegia in patients undergoing heart failure surgery and to propose a risk model. METHODS: A retrospective study including heart failure patients who underwent surgical left ventricular restoration, CorCap implantation or left ventricular assist device implantation between 2006 and 2015. Patients were classified by the presence or absence of vasoplegia. RESULTS: Two hundred and twenty-five patients were included. The incidence of vasoplegia was 29%. The 90-day survival rate in vasoplegic patients was lower compared with non-vasoplegic patients (71% vs 91%, P < 0.001). After adjusting for age, sex and surgical procedure, anaemia (OR 2.195; 95% CI 1.146, 4.204; P = 0.018) and a higher thyroxine level (OR 1.140; 95% CI 1.033, 1.259; P = 0.009) increased the risk of vasoplegia; a higher creatinine clearance (OR 0.980; 95% CI 0.965, 0.994; P = 0.006) and beta-blocker use (OR 0.257; 95% CI 0.112, 0.589; P = 0.001) decreased the risk. The risk model consisted of the same variables and could adequately identify patients at risk for vasoplegia. CONCLUSIONS: Vasoplegia after heart failure surgery is common and results in a lower survival rate. Anaemia and a higher thyroxine level are associated with an increased risk on vasoplegia. In contrast, a higher creatinine clearance and beta-blocker use decrease the risk on vasoplegia. These factors are used in the risk model that may guide treatment strategy.

1 December 2022 in High Altitude Medicine & Biology
Verified
Journal Article
Closed access
RBRemco Berendsen
Remco Berendsen
PBPeter Bärtsch
Peter Bärtsch
BBBuddha Basnyat
Buddha Basnyat
MBMarc Moritz Berger
Marc Moritz Berger
PHPeter Hackett
Peter Hackett
BKBengt Kayser
Bengt Kayser
Berendsen, Remco R., Peter Bärtsch, Buddha Basnyat, Marc Moritz Berger, Peter Hackett, Andrew M. Luks, Jean-Paul Richalet, Ken Zafren, Bengt Kayser, and the STAK Plenary Group. Strengthening altitude knowledge: a Delphi study to define minimum knowledge of altitude illness for laypersons traveling to high altitude. High Alt Med Biol . 23:330–337, 2022. Introduction: A lack of knowledge among laypersons about the hazards of high-altitude exposure contributes to morbidity and mortality from acute mountain sickness (AMS), high-altitude cerebral edema (HACE), and high-altitude pulmonary edema (HAPE) among high-altitude travelers. There are guidelines regarding the recognition, prevention, and treatment of acute-altitude illness for experts, but essential knowledge for laypersons traveling to high altitudes has not been defined. We sought expert consensus on the essential knowledge required for people planning to travel to high altitudes. Methods: The Delphi method was used. The panel consisted of two moderators, a core expert group and a plenary expert group. The moderators made a preliminary list of statements defining the desired minimum knowledge for laypersons traveling to high altitudes, based on the relevant literature. These preliminary statements were then reviewed, supplemented, and modified by a core expert group. A list of 33 statements was then presented to a plenary group of experts in successive rounds. Results: It took three rounds to reach a consensus. Of the 10 core experts invited, 7 completed all the rounds. Of the 76 plenary experts, 41 (54%) participated in Round 1, and of these 41 a total of 32 (78%) experts completed all three rounds. The final list contained 28 statements in 5 categories (altitude physiology, sleeping at altitude, AMS, HACE, and HAPE). This list represents an expert consensus on the desired minimum knowledge for laypersons planning high-altitude travel. Conclusion: Using the Delphi method, the STrengthening Altitude Knowledge initiative yielded a set of 28 statements representing essential learning objectives for laypersons who plan to travel to high altitudes. This list could be used to develop educational interventions.

1 November 2018 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
MVMarieke E. van Vessem
Marieke E. van Vessem
MPMeindert Palmen
Meindert Palmen
LCLotte E. Couperus
Lotte E. Couperus
TSTheo Stijnen
Theo Stijnen
RBRemco Berendsen
Remco Berendsen
SBSaskia L.M.A. Beeres
Saskia L.M.A. Beeres

21 November 2019 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
MVMarieke van Vessem
Marieke van Vessem
SBSaskia L.M.A. Beeres
Saskia L.M.A. Beeres
Robert B. P. De WildeRobert B. P. De Wilde
Robert B. P. De Wilde
RVRené de Vries
René de Vries
RBRemco Berendsen
Remco Berendsen
Meindert PalmenMeindert Palmen
Meindert Palmen
Background: Vasoplegia is a severe complication which may occur after cardiac surgery, particularly in patients with heart failure. It is a result of activation of vasodilator pathways, inactivation of vasoconstrictor pathways and the resistance to vasopressors. However, the precise etiology remains unclear. The aim of the Vasoresponsiveness in patients with heart failure (VASOR) study is to objectify and characterize the altered vasoresponsiveness in patients with heart failure, before, during and after heart failure surgery and to identify the etiological factors involved. Methods: This is a prospective, observational study conducted at Leiden University Medical Center. Patients with and patients without heart failure undergoing cardiac surgery on cardiopulmonary bypass are enrolled. The study is divided in two inclusion phases. During phase 1, 18 patients with and 18 patients without heart failure are enrolled. The vascular reactivity in response to a vasoconstrictor (phenylephrine) and a vasodilator (nitroglycerin) is assessed in vivo on different timepoints. The response to phenylephrine is assessed on t1 (before induction), t2 (before induction, after start of cardiotropic drugs and/or vasopressors), t3 (after induction), t4 (15 min after cessation of cardiopulmonary bypass) and t5 (1 day post-operatively). The response to nitroglycerin is assessed on t1 and t5. Furthermore, a sample of pre-pericardial fat tissue, containing resistance arteries, is collected intraoperatively. The ex vivo vascular reactivity is assessed by constructing concentrations response curves to various vasoactive substances using isolated resistance arteries. Next, expression of signaling proteins and receptors is assessed using immunohistochemistry and mRNA analysis. Furthermore, the groups are compared with respect to levels of organic compounds that can influence the cardiovascular system (e.g. copeptin, (nor)epinephrine, ANP, BNP, NTproBNP, angiotensin II, cortisol, aldosterone, renin and VMA levels). During inclusion phase 2, only the ex vivo vascular reactivity test is performed in patients with (N = 12) and without heart failure (N = 12). Discussion: Understanding the difference in vascular responsiveness between patients with and without heart failure in detail, might yield therapeutic options or development of preventive strategies for vasoplegia, leading to safer surgical interventions and improvement in outcome. Trial registration: The Netherlands Trial Register (NTR), NTR5647. Registered 26 January 2016.